source
- InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testInnoCare Pharma announced Monday that its oral tyrosine kinase 2 (TYK2) inhibitor fadeucravacitinib met the primary endpoint in a phase 3 trial of adults with moderate-to-severe plaque psoriasis.
- After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaborationAfter signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH) candidate seralutinib in 2024, Gossamer Bio has ended the collaborat…